Printer Friendly

Vical to Present at Upcoming Investor Conferences.

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Vical Incorporated will be presenting an overview of the company's independent and collaborative development programs at the BIOCOM Investor Conference in San Diego on Tuesday, October 28, and at the BIO Investor Forum in San Francisco on Wednesday, October 29.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com/.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
 Contact: Alan R. Engbring
 (858) 646-1127
 Website: http://www.vical.com/



CONTACT: Alan R. Engbring of Vical Incorporated, +1-858-646-1127

Web site: http://www.vical.com/
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 23, 2008
Words:338
Previous Article:Quepasa.com Reveals New Free Online Games to Cultivate Interactive Social Community.
Next Article:Alexion Reports Third Quarter 2008 Results.
Topics:


Related Articles
Vical Reports First Quarter 2007 Financial Results; Highlights Progress in Key Development Programs.
Vical to Present at Scientific and Investor Conferences.
Vical to Present at Upcoming Investor Conferences.
Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results.
Vical to Present at Investor Conferences.
Vical to Present at BIO CEO and Investor Conference.
Vical to Present at Upcoming Investor Conferences.
Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines.
Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results.
Vical to Present at Upcoming Investor Conferences.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters